Pirtobrutinib Versus Ibrutinib in Treatment-Naïve and Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

20253 citationsJournal Articlehybrid Open Access

Authors

Jennifer A. Woyach · The Ohio State University

Lugui Qiu · Chinese Academy of Medical Sciences & Peking Union Medical College

Sebastian Grosicki · Medical University of Silesia

Tomasz Wróbel · Wroclaw Medical University

Marcelo Capra · Hospital Mãe de Deus

Jarosław Czyż · Nicolaus Copernicus University

Shuhua Yi

Abstract

Pirtobrutinib demonstrated NI of ORR versus ibrutinib, with a favorable early PFS trend, particularly in TN patients, and a favorable safety profile including low rates of atrial fibrillation and hypertension.

Topics & Keywords

Chronic Lymphocytic Leukemia Research Lymphoma Diagnosis and Treatment Chronic Myeloid Leukemia Treatments

Publication Details

Published in: Journal of Clinical Oncology

Volume 44, Issue 6, pp. 476-485

DOI: 10.1200/jco-25-02477

Field-Weighted Citation Impact: 4.82

Command Palette

Pirtobrutinib Versus Ibrutinib in Treatment-Naïve and Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Authors

Abstract

Topics & Keywords

Publication Details